We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CALITATEA VIEŢII LA PACIENŢII CU REACŢII ADVERSE DERMATOLOGICE LA TERAPII ANTINEOPLAZICE DE NOUĂ GENERAŢIE.
- Authors
Stoica, Cristiana; Giurcăneanu, Călin; Niţipir, Cornelia; Popa, Liliana Gabriela; Ghiordănescu, Ileana; Barbu, Maria Alexandra; Beiu, Cristina; Ghiţă, Ioana Andreea; Mihai, Mara-Mădălina
- Abstract
The development of molecularly targeted therapies and immunotherapies represents a major breakthrough in the field of oncology, with major benefits on the quality of life and progression-free survival of patients. However, targeted therapies are also associated with important side effects that can lead to dose reduction or even cessation of anti-tumor therapy. Dermatological toxicity is among the most common side effects. Objective: We aim to describe dermatological adverse reactions to various novel oncological therapies and to evaluate their impact on patients' quality of life, overall discomfort and skin toxicity-induced depression, using standardized health questionnaires. Materials and methods: We conducted a prospective study of consecutive patients undergoing novel oncologic treatment with targeted therapies or immunotherapy who presented dermatologic side effects. Clinical data was collected by anamnesis and full body examination. Quality of life was assessed using three internationally validated questionnaires: Dermatology Life Quality Index - DLQI, SKINDEX-16, and Patient Health Questionnaire - PHQ9. Results: The most common skin manifestation observed during treatment with epidermal growth factor receptor inhibitors is the papulopustular rash (100%). Sorafenib appears to be responsible for the development of a generalized erythematous macular rash. Nivolumab causes immune dermatological reactions, such as psoriasis. Adverse reactions occurring during oncological treatments have a moderate impact on quality of life and may be associated with mild forms of depression. Women are more psycho-emotionally affected than men. Conclusions: The use of targeted therapies and immunotherapy is constantly increasing in the management of oncologic patients in Romania. A better understanding of the pharmacotoxicological profile of the new agents, their impact on the patients` quality of life, as well as the correct management of their adverse reactions could increase the benefit of these promising therapies.
- Publication
Dermatovenerologia Journal, 2019, Vol 64, Issue 3, p153
- ISSN
1220-3734
- Publication type
Article